Rachel J. Mejdrich builds and manages global patent portfolios for biotechnology and pharmaceutical clients. Using her advanced training in biotechnology, she actively collaborates with bench scientists, business development personnel, and in-house counsel to maximize patent protection in a variety of technologies. She has extensive experience preparing and prosecuting patent applications in the U.S. and foreign countries, preparing legal opinions, and participating in interference and opposition proceedings.
Technologies with which Ms. Mejdrich has been involved include recombinant DNA and expression systems, siRNA, proteins, expression vectors(e.g., viral vectors), vaccines, chemical and biological assays, antibodies, cell lines, pluripotent stem cell technology, immunotherapy, anti-virals, biomarkers, medical treatments including therapies for Alzheimer’s disease and cancer, pharmaceutical compositions and formulations, and enzymatic reactions.
Prior to her employment at Leydig, Voit & Mayer, Ms. Mejdrich worked as a senior research technician at the University of Chicago studying the molecular mechanisms of fragility of the common fragile site, FRA3B, on human chromosome 3p14.2 and its implications in leukemia. Additionally, she held a special term appointment as a molecular biologist at Argonne National Laboratory, where she continued her undergraduate research of studying the reaction center of photosynthetic bacteria Rhodobacter capsulatus and Rhodobacter sphaeroides to investigate photosynthetic properties of the bacteria.